Can Zn Be a Critical Element in COVID-19 Treatment?
Abstract The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale and evidence have been presented to use chloroquine for the treatment of COVID-19. Furthermore, Zn has the ability to enhance innate and adaptive immunity in the course of a viral infection. Besides, Zn supplement can favour COVID-19 treatment using those suggested and/or recommended drugs. Again, the effectiveness of Zn can be enhanced by using chloroquine as an ionophore while Zn inside the infected cell can stop SARS-CoV-2 replication. Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:199 |
|---|---|
| Enthalten in: |
Biological trace element research - 199(2020), 2 vom: 26. Mai, Seite 550-558 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rahman, Mohammad Tariqur [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anti-viral drugs |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2020 |
|---|
| doi: |
10.1007/s12011-020-02194-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2122101350 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2122101350 | ||
| 003 | DE-627 | ||
| 005 | 20230504191717.0 | ||
| 007 | tu | ||
| 008 | 230504s2020 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12011-020-02194-9 |2 doi | |
| 035 | |a (DE-627)OLC2122101350 | ||
| 035 | |a (DE-He213)s12011-020-02194-9-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 100 | 1 | |a Rahman, Mohammad Tariqur |e verfasserin |0 (orcid)0000-0003-3600-3265 |4 aut | |
| 245 | 1 | 0 | |a Can Zn Be a Critical Element in COVID-19 Treatment? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2020 | ||
| 520 | |a Abstract The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale and evidence have been presented to use chloroquine for the treatment of COVID-19. Furthermore, Zn has the ability to enhance innate and adaptive immunity in the course of a viral infection. Besides, Zn supplement can favour COVID-19 treatment using those suggested and/or recommended drugs. Again, the effectiveness of Zn can be enhanced by using chloroquine as an ionophore while Zn inside the infected cell can stop SARS-CoV-2 replication. Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19. | ||
| 650 | 4 | |a Anti-viral drugs | |
| 650 | 4 | |a Chloroquine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a RNA dependent RNA polymerase | |
| 650 | 4 | |a Zinc transporter | |
| 650 | 4 | |a Pneumocytes | |
| 700 | 1 | |a Idid, Syed Zahir |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biological trace element research |d Springer US, 1979 |g 199(2020), 2 vom: 26. Mai, Seite 550-558 |w (DE-627)130077275 |w (DE-600)445336-0 |w (DE-576)015614395 |x 0163-4984 |7 nnns |
| 773 | 1 | 8 | |g volume:199 |g year:2020 |g number:2 |g day:26 |g month:05 |g pages:550-558 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12011-020-02194-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-CHE | ||
| 951 | |a AR | ||
| 952 | |d 199 |j 2020 |e 2 |b 26 |c 05 |h 550-558 | ||